news
HHS clears compounding pharmacies to dispense six popular peptides
Health Secretary Robert F. Kennedy Jr. directed regulators to lift compounding restrictions on six widely sought peptides, including BPC-157 and CJC-1295. The policy lets licensed 503A compounding pharmacies legally prepare and dispense the injectables without standard FDA drug approvals. For athletes and longevity patients, it shifts underground grey-market vials directly onto clinic prescription pads.
Health Secretary Robert F. Kennedy Jr. directed regulators to lift compounding restrictions on six widely sought peptides, including BPC-157 and CJC-1295. The policy lets licensed 503A compounding pharmacies legally prepare and dispense the injectables without standard FDA drug approvals. For athletes and longevity patients, it shifts underground grey-market vials directly onto clinic prescription pads.
The architecture take
I watched my inbox fill up with three clinic blast emails before breakfast (all from doctors I haven't seen in two years). If you spent the last 18 months buying BPC-157 labeled 'for research use only' from sketchy domestic websites, the grey market just went mainstream. I admit I assumed the FDA's 2023 crackdown on Category 2 bulk substances wouldn't budge anytime soon. Instead, compounds like BPC-157, which prompts collagen synthesis and gut mucosal repair through local angiogenesis, and CJC-1295, which nudges pituitary receptors for pulsatile growth hormone release, are heading behind legal pharmacy counters. The real upside is sterility; underground lyophilized powders were always an infection gamble. But I worry about dosing sanity once med-spas bundle them into $800 monthly recovery packages. Peptides are targeted signaling molecules. Pushing cellular proliferation and growth pathways without baseline cancer screenings or structured cycle off-periods is playing with matches. Watch every cash-pay longevity outfit swap their semaglutide promos for peptide repair stacks by next month.